JP2024527537A5 - - Google Patents
Info
- Publication number
- JP2024527537A5 JP2024527537A5 JP2023580373A JP2023580373A JP2024527537A5 JP 2024527537 A5 JP2024527537 A5 JP 2024527537A5 JP 2023580373 A JP2023580373 A JP 2023580373A JP 2023580373 A JP2023580373 A JP 2023580373A JP 2024527537 A5 JP2024527537 A5 JP 2024527537A5
- Authority
- JP
- Japan
- Prior art keywords
- immune effector
- effector cells
- seq
- target portion
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110749475 | 2021-07-01 | ||
| CN202110749475.0 | 2021-07-01 | ||
| PCT/CN2022/103102 WO2023274387A1 (zh) | 2021-07-01 | 2022-06-30 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527537A JP2024527537A (ja) | 2024-07-25 |
| JP2024527537A5 true JP2024527537A5 (cg-RX-API-DMAC7.html) | 2025-07-07 |
Family
ID=84690472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580373A Pending JP2024527537A (ja) | 2021-07-01 | 2022-06-30 | Gd2を標的とするユニバーサルcar-t細胞及びその製造方法並びに使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240139321A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527537A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118019842A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023274387A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023274380A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| WO2025219520A1 (en) * | 2024-04-18 | 2025-10-23 | Match Medicines Gmbh | MODIFIED HUMAN T CELL WITH A REDUCED HLA-Ia REPERTOIRE AND METHOD OF PRODUCTION |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE471946T1 (de) * | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| CA3069527A1 (en) * | 2017-07-12 | 2019-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treatment of cancers harboring an h3k27m mutation |
| CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| CN107630006B (zh) * | 2017-09-30 | 2020-09-11 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| CN108728460A (zh) * | 2018-05-25 | 2018-11-02 | 上海恒润达生生物科技有限公司 | 靶向gd2的嵌合抗原受体及其用途 |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| CN109096405B (zh) * | 2018-09-20 | 2021-07-09 | 杭州普略生物科技有限公司 | 以gd2为靶点的嵌合抗原受体及药物组合物 |
| EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CA3138633A1 (en) * | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| JP7670358B2 (ja) * | 2020-01-02 | 2025-04-30 | 寧波茂行生物医薬科技有限公司 | 修飾された免疫エフェクター細胞及びその調製方法 |
-
2022
- 2022-06-30 JP JP2023580373A patent/JP2024527537A/ja active Pending
- 2022-06-30 WO PCT/CN2022/103102 patent/WO2023274387A1/zh not_active Ceased
- 2022-06-30 US US18/575,451 patent/US20240139321A1/en active Pending
- 2022-06-30 CN CN202280046726.1A patent/CN118019842A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250136700A1 (en) | Bispecific antibody for cancer immunotherapy | |
| US20220047633A1 (en) | Cd22 chimeric antigen receptor (car) therapies | |
| US20210347851A1 (en) | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies | |
| TWI854953B (zh) | 抗cd3抗體及含有該抗體的分子、及其製造方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| KR20220035367A (ko) | 항-dll3 키메라 항원 수용체 및 이의 용도 | |
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| TW202340473A (zh) | 利用嵌合抗原受體之癌症治療 | |
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2018504113A (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| TW201708261A (zh) | Dll3及cd3抗體構築體 | |
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| JP2019530431A5 (cg-RX-API-DMAC7.html) | ||
| JP2022542559A5 (cg-RX-API-DMAC7.html) | ||
| JP2018162269A (ja) | P2x7受容体アンタゴニスト及びアゴニスト | |
| JP2024509910A (ja) | Mage-a4ペプチド-mhc抗原結合タンパク質 | |
| JP2021072773A (ja) | p53−MHCクラスI複合体に結合するT細胞受容体様抗体 | |
| TW202346368A (zh) | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 | |
| JP2024516308A5 (cg-RX-API-DMAC7.html) | ||
| WO2015172341A1 (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| JP2024012258A (ja) | Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| JP2025532313A (ja) | Cd3を標的とする抗体及びその用途 | |
| JP2024527539A5 (cg-RX-API-DMAC7.html) | ||
| WO2022002006A1 (zh) | Fab-HCAb结构的结合蛋白 | |
| US20250092154A1 (en) | Anti-mesothelin antibodies and uses thereof |